---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-042822"
form_type: "8-K"
ticker: "DXR"
cik: "0000027367"
company_name: "DAXOR CORP"
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:14:47.751946+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Daxor allocates $550K of May 2023 offering proceeds to hematocrit capability development

## Summary
- Net proceeds of $3.56M from May 22, 2023 public offering of 410,260 shares at $9.75/share.
- $550,000 reserved for proprietary hematocrit capability for next-generation technologies.
- Development expected over 12 months, supported by Department of Defense efforts.
- Funds are part of the previously stated use of proceeds for next-gen technology development.

## SEC filing metadata
- accession: 0001493152-23-042822
- form_type: 8-K
- ticker: DXR
- cik: 0000027367
- company_name: DAXOR CORP
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/27367/000149315223042822/0001493152-23-042822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/27367/000149315223042822/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-042822
- JSON: https://secwatch.observer/filing/0001493152-23-042822.json
- Plain text: https://secwatch.observer/filing/0001493152-23-042822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.